Basic Information
Efmody
Regulatory Information
EMEA/H/C/005105
May 27, 2021
March 25, 2021
6
November 15, 2024
Company Information
Neurocrine Netherlands B.V.,Van Heuven Goedhartlaan 935 A,1181 LD Amstelveen,NETHERLANDS
Netherlands
Van Heuven Goedhartlaan 935 A 1181 LD Amstelveen
neurocrine netherlands b.v.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.
Overview Summary
Efmody is a medicine used to treat an inherited condition called congenital adrenal hyperplasia (CAH) in patients 12 years old and above. CAH is rare, and Efmody was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 27 July 2005. Further information on the orphan designation can be found [here](/en/medicines/human/orphan-designations/eu-3-05-296). Efmody contains the active substance hydrocortisone and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but Efmody has a different use and is available in different strengths as capsules formulated to release the active substance over a prolonged period. The reference medicine for Efmody capsules is Hydrocortone tablets.